Follow US:
New startups developing health and diagnostic technologies May 11, 2021 May 11, 2021
Two new tenants have joined the UC Riverside Life Sciences Incubator as the campus continues to ramp-up research and provide lab and office space for life science entrepreneurs.
NeyroblastGX and GattaCo Inc. are the third and fourth tenants to join the state-of-the-art research facility housed in the Multidisciplinary Research Building. Karamedica Inc. and Murrieta Genomics Inc. were the first two tenants in the incubator, which is managed by the UC Riverside Office of Technology Partnerships.
NeyroblastGX, which was founded last year, began working out of the incubator in January and has received funding from the U.S. Department of Defense, Defense Advanced Research Projects Agency, and the National Science Foundation.
Murrieta (PRWEB) April 21, 2021 Murrieta Genomics, the launch pad for genomic sequencing startups, has announced that simplSEQ, an incubator company, has
Dr. John C. Spinosa Joins Murrieta Genomics as Chief Medical Officer
Share Article
Addition of noted pathologist to executive team provides insights into precision medicine and critical connections to the greater life science community.
Dr. John C. Spinosa MURRIETA, Calif. (PRWEB) February 02, 2021
Murrieta Genomics, the launch pad for genomic sequencing startups, has announced that John C. Spinosa, M.D., Ph.D., has joined the executive management team. He has also been appointed as Chief Medical Officer of SimplSEQ, Inc., a wholly owned subsidiary of Murrieta Genomics.
“We are fortunate to have attracted Dr. Spinosa to join us,” stated Jay Goth, CEO. “John’s background and experience with companies large and small will be critical to our future success helping genomic sequencing companies revolutionize the healthcare, agriculture and forensic industries. His reputation as a leading pathologist is well
Murrieta Genomics Spinout SimplSeq Files Fourth Patent Application Around Novel Sample Preparation Technology
Share Article
Sequencing. Simplified. MURRIETA, Calif. (PRWEB) December 22, 2020
Murrieta Genomics has announced that SimplSeq, Inc., a wholly owned subsidiary, has filed its fourth patent application to protect a new sample preparation technology that is designed to simplify the process for extracting, isolating, purifying and replicating DNA and RNA from biologic samples.
“Our internal validation testing has delivered some very exciting data, and we wanted to share that with collaborators,” stated John Powers, CEO of SimplSeq. “When we delivered these results to our legal team, they immediately informed us that we needed to file an additional application with the Patent and Trademark Office.”